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0.781–0.994. Factor scores were compared across self-re-
ported degree of impact. For discriminate validity, the
staff placed each consumer into one of 4 quartiles to de-
scribe their perception of the consumer’s ability to func-
tion in each factor area. Consumer factor scores then
were compared to staff-reported functional levels. RE-
SULTS: For all factors, consumer factor scores progres-
sively lowered as consumers felt the condition had more
negative impact on their lives (P  0.001). For all factors
but medication effects, consumer factor scores improved
with improving staff-perceived assessment of consumer
functionality (P  0.001). Consumer scores from the
lowest to the highest assigned quartile had average scores
of 42.7%, 49.3%, 54.7%, and 60.0%, respectively. 92%
of consumers considered the survey useful, 92% of staff
considered the survey valuable for monitoring consumer
progress. CONCLUSION: We have established concur-
rent and discriminatory validity for the SOAP-51 which
can be used as an outcomes measure in patient monitor-
ing and management, and health policy decision making. 
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PATIENT PREFERENCES FOR TREATMENT 
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OBJECTIVES: One of the most disconcerting symptoms
associated with Parkinson’s disease (PD) and essential
tremor (ET) is disabling tremor. Treatment options for
this problem include low-risk pharmacologic therapy,
with generally poor effectiveness and unfavorable side ef-
fects, or higher risk surgical interventions such as thalam-
otomy. We describe the health-related quality of life
(HRQL) of patients with disabling tremor and assess
their preferences for treatment outcomes in the form of
utilities. METHODS: The MOS Short-Form 36 (SF-36)
was used to characterize the patients’ HRQL. Standard
gamble (SG) and visual analog scale (VAS) approaches
were used to determine patient preferences among 12 PD
and 9 ET health state descriptions. Data on patients’ ap-
praisal of their current health state were also correlated
with indicators of functional disability (Schwab & En-
gland) and HRQL (SF-36) using Spearman’s Rho (	). RE-
SULTS: Sixty-two patients, 31 tremor-dominant PD and
31 ET, participated in the study. Mean age of the sample
was 65 years; 65% (n  40) were male. PD and ET pa-
tients assigned the lowest mean SG health utilities to the
health state description for a thalamotomy with partial
or no improvement and permanent cognitive impairment
(mean  standard deviation: PD: 0.56  0.25 and ET:
0.49  0.27). The highest mean utilities were assigned to
thalamotomy with full improvement and no permanent
impairment (PD: 0.95  0.02 and ET: 0.90  0.18). Cur-
rent health state SG utilities were highly correlated with
indicators of disability and HRQL (	  0.35 to 0.64).
CONCLUSIONS: Results suggest these patients are rela-
tively risk averse. Subjects preferred disability associated
with tremor over disability associated with cognitive or
speech impairment that can occur with thalamotomy.
The greatest patient-to-patient variability was found in
the least desirable health states.
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OBJECTIVES: To compare clinical characteristics, treat-
ment choices, sociodemographic features, baseline and
follow-up HRQOL of African American (AA) and Cau-
casian men with prostate cancer. METHODS: 1178 newly
diagnosed patients (82% Caucasian, 12% AA) from the
CaPSURE database (a national database of patients with
prostate cancer) were studied. Baseline cancer stage,
grade, PSA, comorbidity, treatment selection and base-
line and post-treatment HRQOL were assessed using the
SF-36 and the UCLA Prostate Cancer Index. The impact
of ethnicity on these outcomes was determined. RE-
SULTS: Significant differences (P  0.001) were noted
between ethnic groups. AA men were younger, less edu-
cated and had lower income than Caucasians. AA men
were more likely to have high-stage (i.e. N or M)
(10% vs. 1%) disease and higher pretreatment PSA (12.7
ng/ml vs. 7.5 ng/ml). AA men were more commonly
treated with androgen deprivation (37% vs. 26%). Clini-
cally and statistically significant (
  7, P  0.001) dif-
ferences in baseline HRQOL were noted in AA men who
had poorer: General Health, Physical Function, Bodily
Pain, Role Emotional Function, Sexual Bother, Self Es-
teem, and Health Distress. While both groups improve in
HRQOL 18 months after treatment, AA had worse out-
come in several domains: Bodily Pain, Self Esteem, Health
Distress, Physical Function, General Health, Role Emo-
tional, Urine Function and Bother, Bowel Function and
Bother. Differences were statistically and clinically signif-
icant. CONCLUSIONS: Significant differences exist in
baseline clinical presentation, sociodemographics, and
general HRQOL between AA and Caucasian men with
prostate cancer. These differences remain after treatment.
Interventions, which might reduce these differences, need
to be developed.
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An estimated 10–20% of adults suffer from IBS, a func-
tional gastrointestinal disorder that negatively affects pa-
tient’s quality of life (QoL). As part of a one-year random-
ized, double blind, placebo-controlled study (S3B30006) of
the 5HT3 receptor antagonist alosetron in women with
IBS, QoL was assessed using the IBSQOL. OBJECTIVE:
To determine the smallest score change on each IBSQOL
scale that can be considered meaningful to the patient.
METHODS: The IBSQOL consists of nine scales, each
yielding a score of 0–100, with higher scores representing
better QoL. Subjects completed the IBSQOL at baseline
and both the IBSQOL and a global assessment question-
naire at months 1 and 2. The global assessment question-
naire contained nine items corresponding to the nine
scales of the IBSQOL. For each item, subjects rated the
change, if any, in a specific aspect of QoL relative to
baseline on a 7-point scale, ranging from “markedly
worse” to “markedly improved.” For each IBSQOL
scale, the average change score for subjects rating them-
selves as “slightly improved,” irrespective of treatment
group, was calculated to establish the minimum mean-
ingful difference (MMD). Average change scores for
“moderately improved” subjects were also calculated.
RESULTS: The MMDs were based on 90–127 subjects
per scale with the exception of sexual relations (n  46).
The following MMDs were determined: emotional—16.9
(SD  20.2); mental health—9.0 (18.7); sleep—11.6
(19.0); energy—18.6 (20.8); physical functioning—11.3
(19.0); food—12.5 (18.6); social functioning—14.5 (17.9);
role-physical—18.9 (19.1); sexual relations—19.4 (19.7).
Score changes corresponding to moderate improvements
were: emotional—24.8 (23.7); mental health—18.4
(18.6); sleep—18.4 (19.0); energy—30.4 (25.1); physical
functioning—20.8 (20.3); food—21.3 (19.4); social func-
tioning—27.2 (20.3); role-physical—27.4 (25.0); sexual
relations—26.1 (26.3). CONCLUSION: Determination
of MMDs for the IBSQOL may serve as a useful interpre-
tive tool.
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INCORPORATING MEASUREMENT OF INDIRECT 
COSTS IN THE EVALUATION OF AN ASTHMA 
HEALTH MANAGEMENT PROGRAM
Ershoff DH, Buchner DA
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Evaluations of Integrated Therapeutics Group (ITG)
Asthma Health Management (AHM) programs have in-
cluded measures of clinical outcomes, utilization/medical
expenditures and QoL. To date, indirect costs have not
been systematically assessed. OBJECTIVES: As part of
an effort to develop and validate survey measures of pro-
ductivity, this study will present significant correlates of
baseline (pre-AHM implementation) mean annual costs
associated with missed days from work due to asthma.
METHODS: Data were obtained from self-reports from
a random sample of adult, employed asthmatics who
completed a mailed survey (N  1275) prior to participa-
tion in an AHM program. The dependent variable was
mean annual costs associated with missed days from
work due to asthma, derived by annualizing missed days
reported in the survey and multiplied by an estimate of
wages. Independent variables included sociodemograph-
ics, health status measures, asthma-related symptomatol-
ogy, utilization of medical services/pharmaceuticals, atti-
tudes and beliefs. RESULTS: Mean annual indirect costs
were $647 (95% CI $541–$754). In order of entrance
into a multiple regression equation, significant predictors
(P  0.05) of increased costs were: 1) asthma-related ER/
inpatient episode; 2) rating of health status as fair/poor;
3) low self-confidence in ability to manage asthma); 4)
adverse symptomatology profile; (5) comorbidity of res-
piratory allergies; and 6) daily use of bronchodilators. As
obtained from the multivariate model, an ER/inpatient
episode generated an increase of $998 associated with
missed work days, and relative to their more confident
counterparts, patients with less confidence had increased
expenditures of $344. CONCLUSIONS: Consistent with
national data, this study reveals a substantial indirect
cost burden associated with asthma. One year follow-up
data on the impact of the ITG AHM program on these
indirect costs will be presented.
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THE RELATIVE EFFECTIVENESS OF SELECTIVE 
SEROTONIN REUPTAKE INHIBITORS (SSRIS) 
AND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN 
REDUCING WORKER ABSENTEEISM
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OBJECTIVE: This paper investigates the extent to which
absenteeism among newly diagnosed, employed patients
with depression varied among those who initiated treat-
ment with a TCA or SSRI. Subjects were drawn from the
MEDSTAT® Group’s MarketScan® and Illumina® Da-
tabases. METHODS: These databases include informa-
tion on the health care use of workers of large employers
in the US. The final analytical sample contained 716
newly diagnosed employees between 1994–1996 who
had absenteeism data available. Patterns of absenteeism
over the six-months prior to and twelve-months follow-
ing the initiation of pharmacotherapy were examined. In
addition, the number of absences during the twelve-
month follow-up period was analyzed using a multivari-
ate regression method specifically designed for non-nega-
tive dependent variables. RESULTS: Mean monthly ab-
sences equaled 4.7 at six-months prior to drug treatment
and rose to 10.2 during the month of initial antidepres-
sant treatment. Six-months after antidepressant treat-
ment commenced, absences declined approximately 40%
to 6 per month. The mean number of total absences dur-
